Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Pregabalin (PRE) acts as a presynaptic inhibitor of the release of excessive levels of excitatory neurotransmitters by selectively binding to the α 2-δ subunit of voltage-gated calcium channels. In this randomised, double-blind comparison trial with naltrexone (NAL), we aimed to investigate the efficacy of PRE on alcohol drinking indices. Craving reduction and improvement of psychiatric symptoms were the secondary endpoints. Seventy-one alcohol-dependent subjects were detoxified and subsequently randomised into two groups, receiving 50 mg of NAL or 150—450 mg of PRE. Craving (VAS; OCDS), withdrawal (CIWA-Ar) and psychiatric symptoms (SCL-90-R) rating scales were applied. Alcohol drinking indices and craving scores were not significantly different between groups. Compared with NAL, PRE resulted in greater improvement of specific symptoms in the areas of anxiety, hostility and psychoticism, and survival function (duration of abstinence from alcohol). PRE also resulted in better outcome in patients reporting a comorbid psychiatric disorder. Results from this study globally place PRE within the same range of efficacy as that of NAL. The mechanism involved in the efficacy of PRE in relapse prevention could be less related to alcohol craving and more associated with the treatment of the comorbid psychiatric symptomatology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Follow-up Study of Anxiety Disorder and Alcohol Dependence in Comorbid Alcoholism Treatment Patients
Kushner, M. G., Abrams, K., Thuras, P., Hanson, K. L., Brekke, M., & Sletten, S. (2005) · Alcoholism: Clinical & Experimental Research · doi:10.1097/01.alc.0000175072.17623.f8 · Cited by 244
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176
Reduction in heavy drinking as a treatment outcome in alcohol dependence
Gastfriend, D. R., Garbutt, J. C., Pettinati, H. M., & Forman, R. F. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.09.008 · Cited by 139
Clorazepate and lorazepam: clinical improvement and rebound anxiety
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.3.312 · Cited by 50
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“6 mg/day) has been shown to result in similar abstinent or heavy drinking days as naltrexone (50 mg/day) (Martinotti et al., 2010) (Ib).”
BackgroundPharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
“These beneficial effects of pregabalin on abstinence, craving and negative affect were replicated in a 16-week randomized, double-blind comparison trial (N = 70) of pregabalin (150–450mg/d) versus naltrexone (50 mg/d) [87].”
Carrus, D., & Schifano, F. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272864d · Cited by 49
Pharmacotherapy for alcohol use disorder.
Holt, S. R., & Tobin, D. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.008 · Cited by 17
Metadata
- Authors
- Martinotti, G., Di Nicola, M., Tedeschi, D., Andreoli, S., Reina, D., Pomponi, M., Mazza, M., Romanelli, R., Moroni, N., De Filippis, R., Di Giannantonio, M., Pozzi, G., Bria, P., & Janiri, L.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-04-03
- Volume
- 24
- Issue
- 9
- Pages
- 1367-1374
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2126145291
- Cited by
- 81
- References
- 9
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. https://app.cochat.ai/papers/10.1177/0269881109102623
- The paper
- Martinotti, G., Di Nicola, M., Tedeschi, D., Andreoli, S., Reina, D., Pomponi, M., Mazza, M., Romanelli, R., Moroni, N., De Filippis, R., Di Giannantonio, M., Pozzi, G., Bria, P., & Janiri, L. (2010). Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881109102623
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.